Friday, 6 November 2026European Markets

MERCIALYS, WERELDHAVE BELGIUM, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - mercialys (mery.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
mercialys (mery.pa) €8.22 11.25% 6.11%
wereldhave belgium (wehb.br) €45.80 9.23% 5.61%
texaf (texf.br) €34.00 4.68% 7.98%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. mercialys (mery.pa)

11.25% forward dividend yield and 6.11% return on equity

mercialys is one of france's leading real estate companies. it is specialized in the holding, management and transformation of retail spaces, anticipating consumer trends, on its own behalf and for third parties. at june 30, 2023, mercialys had a real estate portfolio valued at euro 3.0 billion (including transfer taxes). its portfolio of 2,054 leases represents an annualized rental base of euro 172.8 million. mercialys has been listed on the stock market since october 12, 2005 (ticker: mery) and has “siic” real estate investment trust (reit) tax status. part of the sbf 120 and euronext paris compartment b, it had 93,886,501 shares outstanding at june 30, 2023.

earnings per share

as for profitability, mercialys has a trailing twelve months eps of €0.66.

pe ratio

mercialys has a trailing twelve months price to earnings ratio of 12.45. meaning, the purchaser of the share is investing €12.45 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.11%.

moving average

mercialys's value is below its 50-day moving average of €8.30 and below its 200-day moving average of €8.99.

yearly top and bottom value

mercialys's stock is valued at €8.22 at 17:30 est, way under its 52-week high of €10.79 and way above its 52-week low of €7.41.

more news about mercialys.

2. wereldhave belgium (wehb.br)

9.23% forward dividend yield and 5.61% return on equity

wereldhave belgium is a public regulated real estate company with a focus on commercial property in belgium. wereldhave belgium targets its new investments on shopping centres. the value of the real estate portfolio, including project developments, amounted to € 921.2 mln on 31 december 2020. on 31 december 2020 the existing operational retail portfolio amounted to € 817.8 mln (around 90% of the total portfolio) and it includes shopping centres in liège, nivelles, tournai, genk and kortrijk and retail parks in brugge, ghent, turnhout, waterloo and tournai. in addition, the portfolio of real estate investments includes offices in vilvoorde and antwerp. as of 31 december 2020 the development portfolio of € 12.6 mln contained land holdings and realised investments that relate to the refurbishment and/or expansion of shopping centres in waterloo and liège.

earnings per share

as for profitability, wereldhave belgium has a trailing twelve months eps of €4.22.

pe ratio

wereldhave belgium has a trailing twelve months price to earnings ratio of 10.85. meaning, the purchaser of the share is investing €10.85 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.61%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, wereldhave belgium's stock is considered to be overbought (>=80).

revenue growth

year-on-year quarterly revenue growth grew by 10.8%, now sitting on 63.4m for the twelve trailing months.

yearly top and bottom value

wereldhave belgium's stock is valued at €45.80 at 17:30 est, way under its 52-week high of €57.20 and higher than its 52-week low of €45.30.

more news about wereldhave belgium.

3. texaf (texf.br)

4.68% forward dividend yield and 7.98% return on equity

texaf s.a. develops, owns, and leases real estate properties in kinshasa. it operates through real estate, digital, and quarries segments. the company's portfolio comprises 332 homes, including 53 villas and 289 apartments with a residential area of 62,200 square meters; 26,300 square meters of office and commercial space; and 30,000 square meters of warehouses, as well as texaf digital campus. it also supplies sandstones for use in concrete production, asphalt for roads, and civil engineering projects. texaf s.a. was founded in 1925 and is headquartered in brussels, belgium. texaf s.a. is a subsidiary of société financière africaine.

earnings per share

as for profitability, texaf has a trailing twelve months eps of €2.02.

pe ratio

texaf has a trailing twelve months price to earnings ratio of 16.83. meaning, the purchaser of the share is investing €16.83 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.98%.

dividend yield

according to morningstar, inc., the next dividend payment is on may 24, 2023, the estimated forward annual dividend rate is 1.57 and the estimated forward annual dividend yield is 4.68%.

more news about texaf.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com